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Abstract
Background: It is desirable that those at highest risk of cardiovascular disease should have priority for preventive
measures, eg. treatment with prescription drugs to modify their risk. We wanted to investigate to what extent
present use of cardiovascular medication (CVM) correlates with cardiovascular risk estimated by three different risk
scores (Framingham, SCORE and NORRISK) ten years ago.
Methods: Prospective logitudinal observational study of 20 252 participants in The Hordaland Health Study born
1950-57, not using CVM in 1997-99. Prescription data obtained from The Norwegian Prescription Database in 2008.
Results: 26% of men and 22% of women aged 51-58 years had started to use some CVM during the previous
decade. As a group, persons using CVM scored significantly higher on the risk algorithms Framingham, SCORE and
NORRISK compared to those not treated. 16-20% of men and 20-22% of women with risk scores below the high-
risk thresholds for the three risk scores were treated with CVM, while 60-65% of men and 25-45% of women with
scores above the high-risk thresholds received no treatment. Among women using CVM, only 2.2% (NORRISK), 4.4%
(SCORE) and 14.5% (Framingham) had risk scores above the high-risk values. Low education, poor self-reported
general health, muscular pains, mental distress (in females only) and a family history of premature cardiovascular
disease correlated with use of CVM. Elevated blood pressure was the single factor most strongly predictive of CVM
treatment.
Conclusion: Prescription of CVM to middle-aged individuals by large seems to occur independently of estimated
total cardiovascular risk, and this applies especially to females.
Background
The ability to predict future risk of cardiovascular disease
(CVD) in asymptomatic persons, in order to implement
preventive measures, is important for clinicians as well as
for public health. Several risk predicting tools have been
developed for this purpose [1-4] and electronic decision
aids are available for rapid risk estimation in daily clinical
work. Unfortunately, these tools are probably still under-
used in clinical practice, where interventions commonly
have been based on assessment of single risk factors like
blood pressure or serum cholesterol [5,6]. From a public
health perspective it is desirable that those at highest risk
should have priority for preventive measures, eg. with
prescription drugs to modify their risk for CVD. It is,
however, not known to which extent those at highest risk
based on a total risk assessment correspond to those who
during follow-up are actually treated with cardiovascular
medication (CVM).
In this prospective longitudinal observational study in
a Norwegian population born 1950-57, we investigated
to which extent results from three different risk score
algorithms (Framingham, SCORE and NORRISK) pre-
dicted use of CVM ten years later [1-3]. Our aim was to
explore whether those being “at risk” according to their
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risk scores, corresponded to individuals who subse-
quently had been put on drug treatment. We also stu-
died if factors normally not included in risk score
algorithms-such as educational level, psychological dis-
tress, and self-evaluated general health-predicted use of
CVM ten years later.
Methods
Study design, setting, participants, outcome variables,
and data sources
In this population based, longitudinal observational
study, a total of 20 252 men and women born 1950-57
and living in Hordaland County in Western Norway
participated. Their individual cardiovascular risk was
mapped in 1997-99, and in 2008 their use of CVM was
investigated. Data sources were the Hordaland Health
Study (1997-99) and the Norwegian Prescription Data-
base (2008).
The Hordaland Health Study (HUSK)
In 1997-99 a population based health survey was carried
out in Hordaland County in Western Norway: The Hor-
daland Health Study (HUSK) [7]. Those invited were a
randomly selected sample of men and women born in
1950 and 1951 (n = 4 849), and all inhabitants born
between 1953 and 1957 (n = 29 400). The survey
included a questionnaire, addressing smoking, medica-
tion use, self-reported diabetes mellitus and cardio- and
cerebrovascular disease (including a family history). Par-
ticipants also attended a mobile screening station pro-
vided by the National Health Screening Service, Oslo
(now the Norwegian Institute of Public Health), where
strictly standardized measurements of systolic-(SBP) and
diastolic blood pressure (DBP), height, weight, choles-
terol, triglycerides and glucosis levels were carried out.
The population included in HUSK is found to be repre-
sentative for the Norwegian population as such [7].
Participants in the present study
Of the 33 549 individuals born 1950-57 invited to parti-
cipate in HUSK, 22 289 (66.6%) responded: 10 249 men
(59.1%) and 12 040 women (74.3%). The 9 283 men
(90.6%) and 10 969 women (91.1%) not using any CVM
in 1997-99, comprised the target population for the pre-
sent study (Table 1).
The Norwegian Prescription Database (NorPD)
The Norwegian Prescription Database (NorPD) provides
information on all prescription drugs dispensed from
Norwegian pharmacies [8]. The register includes infor-
mation on patients’ gender and date of birth, prescri-
bers’ age, sex and clinical specialty, and prescription
details according to the Anatomical Therapeutic Chemi-
cal (ATC) classification system [9].
In the present study we investigated HUSK-participants’
(1997-99) use of prescription CVM in 2008 (record linkage
with NorPD data). CVMs were defined as drugs with ATC
codes C01 (cardiac therapy), C02 (antihypertensives), C03
(diuretics), C07 (beta blocking agents), C08 (calcium chan-
nel blockers), C09 (agents acting on the renin-angiotensin
system), and C10 (lipid modifying agents).
Risk algorithms
On the basis of data recorded in HUSK during 1997-99,
we were able to apply the following risk algorithms,
which are all intended for risk stratification for primary
prevention of CVD:
• The Framingham risk algorithm published in 1991
predicts the ten year risk for all kinds of coronary
events, fatal and non-fatal [1]. A Framingham risk score
of ≥20% is regarded as high risk.
• The SCORE (Systematic Coronary Risk Evaluation)
risk algorithm presented in 2003 is based on a pooled
dataset of cohort studies from 12 European countries,
including Norway [2]. It predicts any kind of fatal CVD
event over a ten-year period. The threshold for being at
high risk is defined as ≥5%.
We extrapolated the values of Framingham and
SCORE to the age of 60 years.
• The NORRISK risk algorithm [3]. This risk model from
2008 is based on updated Norwegian data regarding age-
and sex specific CVD mortality rates. The NORRISK
algorithm estimates the ten year risk of fatal CVD by com-
bining gender, age, systolic blood pressure, total cholesterol
and smoking. The threshold for high risk is set at ≥5%.
Statistics and ethics
Statistical analyses were carried out using SPSS version 18.
Bivariate comparisons were done by chi-square test
Table 1 Age and sex distribution of participants (n = 22
298) in The Hordaland Health Study (HUSK) 1997-99 and
participants (n = 20 252) included in the 2008 record
linkage study, where individuals using cardiovascular
medication (CVM) in 1997-99 had been excluded (n = 2 046)
Birth
year
1997-99 2008
Males n (%) Females
n (%)
Males n (%) Females
n (%)
1950 881 (8.6) 1 067 (8.9) 833 (9.0) 1 028 (9.4)
1951 783 (7.6) 1 002 (8.3) 745 (8.0) 967 (8.8)
1953 1 725 (16.8) 1 982 (16.4) 1 661 (17.9) 1 755 (16.0)
1954 1 721 (16.8) 2 023 (16.8) 1 390 (15.0) 1 796 (16.4)
1955 1 703 (16.6) 2 036 (16.9) 1437 (15.5) 1 641 (15.0)
1956 1 721 (16.8) 1 996 (16.6) 1 647 (17.7) 1 931 (17.6)
1957 1 715 (16.7) 1 943 (16.1) 1 570 (16.9) 1 851 (16.9)
Total 10 249
(100%)
12 049 (100%) 9 283
(100%)
10 969 (100%)
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(categorical variables) or independent samples t-test (coni-
tuous variables).
The study was approved by the Regional Committee
for Medical Research Ethics and the Norwegian Data
Inspectorate, for the 1997-99 as well as the 2008 data
collection. A written consent allowing future use of
their data for research was obtained from each HUSK-
participant at the screening station.
Results
During the 9-11 years from 1997-1999 to 2008, 26% of
men (n = 2 411) and 22% of women (n = 2 448) not on
CVM in 1997-99, had started such treatment (Table 2).
14.4% of men and 9.4% of women used more than one
CVM. 14.2% of men and 9.6% of women used a statin
and 5.6% of men and 4.6% of women used a statin as
their only treatment. The proportion using CVM tended
to increase with patients’ age: for men from 21.3% for
those born in 1957 to 34.1% for those born in 1950, cor-
responding figures for females were 17.1% and 30.4%
(Table 2).
Table 3 shows the 1997-99-values for the Framing-
ham, SCORE and NORRISK cardiovascular risk algo-
rithms for those who had started medication during the
period from 1997-1999 to 2008 versus those who had
not. For both genders all risk scores showed significantly
lower values for those not on CVM compared to those
now on treatment. Female CVM users had significantly
lower total risk score values compared to both males
taking and not taking CVM (p-values not shown in
table).
Table 4 shows the proportion of men and women
with cardiovascular risk scores at threshold or above
and below “high risk” values in 1997-99 who used CVM
in 2008. For this calculation we chose a “high risk” limit
for NORRISK at ≥1% [3], as only 13 males and no
females in our study population scored equal to or
above the somewhat arbitrarily set limit of 5%. Among
men with risk scores below the critical limits for the
three different risk algorithms, 16-20% were using some
CMV in 2008, for women this proportion was 20-22%.
Among men with risk score values on thershold or
above the “high risk” limits, 35-40% used CVM in 2008.
Among the relatively few women above these limits, 56-
72% had started using some CVM. Among women
using CVM, only 2.2% (NORRISK), 4.4% (SCORE) and
14.5% (Framingham) had risk scores above the high-risk
thresholds. The table also shows that 83% of men and
88% of women with blood pressure above 150/90 were
treated, while 58% of men and 64% of women with a
cholesterol level higher than 8 mmol/l used CVM.
Table 5 shows characteristics for females and males
taking or not taking CVM. Compared to women not
using CVM, women on medication reported poorer gen-
eral and mental health, more muscular pains, more use
of other medications, less physical exercise, less use of
alcohol, and more were smokers. They also had a lower
educational level, and reported a higher frequency of
CVD in close relatives. Their BMI, SBP, DBP, total cho-
lestrol, triglycerides, and glucosis values were all signifi-
cantly higher and their HDL-cholesterol lower
compared to those not using CVM. For men, there was
no difference regarding mental health, use of alcohol or
smoking between those using or not using CVM. For
the remaining factors, the differences between the
groups corresponded to those seen among females.
Compared to men on CVM, women on treatment
reported poorer general and mental health, more mus-
cular pains, more use of other medications, and fewer
carried out hard physical exercise (Table 5, p-values not
shown in Table). However, relatively more men reported
they were physically inactive, and fewer reported no use
of alcohol. Women had more favourable values for BMI,
SBP, DBP, total- and HDL-cholestrol, triglycerides and
glucosis compared to men, and they were generally less
educated compared to their male counterparts.
For both genders, all risk algorithms showed a signifi-
cant correlation with mental distress (Table 6).
Out of the 22 241 persons originally included in the
study, 343 persons were reported to have died at some
point between the data collection in 1997-99 and
December 2009 (data from the National Population Reg-
istry). 152 out of these 343 persons could be traced in
Table 2 Use of cardiovascular medication (CVM) in 2008
among persons not on treatment in 1997-99: Males:
n = 9 283, females: n = 10 969
Birth
year Sex
CVM (%)
CVM ≥1 drug Statin Statin alone
1950 M 34.1 20.0 18.8 7.1
F 30.4 11.5 13.4 7.1
1951 M 28.7 15.8 16.6 6.4
F 24.9 10.4 10.9 5.8
1953 M 30.0 17.2 16.0 6.2
F 23.5 10.9 10.5 4.6
1954 M 26.9 15.5 15.3 5.4
F 24.8 10.7 11.4 6.1
1955 M 23.4 12.6 12.6 5.1
F 20.6 8.0 9.1 4.5
1956 M 22.5 12.3 12.0 5.1
F 19.7 8.6 7.6 3.3
1957 M 21.3 10.7 11.5 5.4
F 17.1 7.1 6.5 2.9
Total M 26.0 14.4 14.2 5.6
F 22.3 9.4 9.6 4.6
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the Norwegian Cancer Registry [7]. Among the remain-
ing 191 individuals, some probably died of cardiovascu-
lar disease, but we do not consider this small number to
influence our results significantly.
Discussion
In this study we found that close to one in four persons
51-58 years of age had started to use some CVM during
the previous decade: 22% of women and 26% of men.
Around one in eight used more than one drug and a
corresponding proportion used a statin.
High cardiovascular risk scores (Framingham, SCORE
and NORRISK) calculated 9-11 years previously were all
significantly associated with subsequent medication use,
although there was a substantial overlap: A considerable
proportion of individuals with risk scores below the
“high-risk” thresholds used CVM (males from 16 to 20%
of the cohort for the three included risk algorithms,
females 20-22%). Among women using CVM, at least
eight out of ten had risk score values below the defined
“high-risk” thresholds. On the other hand, around 60%
of men with risk scores above the “high risk” level, did
not use any CVM. Even in the group of men with risk
score levels on or above the 90th percentile (correspond-
ing to Framingham at 60 years 33.87, SCORE at 60
years 11.15 and NORRISK 1.61) 47-48% used no CVM
(data not shown in table). It may thus seem that pre-
scription of CVM to a large degree had occured inde-
pendently of the patient’s total cardiovascular risk, as
expressed by these commonly used risk algorithms.
Maybe even more striking is that the proportion of
females on medication roughly corresponded to that of
males (22.3% versus 26.0%), despite females’ substan-
tially lower risk score levels-the majority of women on
CVM had risk score levels well below the “high-risk”
limits.
The study has some limitations. It was done by a
population survey and a subsequent linkage to a pre-
scription database, not by intentionally following a well
designed cohort. Among others, we can not tell if the
medications had been prescribed for present CVD or for
primary- or secondary prevention. The response rate of
the population survey was as high as 66.6%, but those
not participating were found to differ from participants
on several aspects, as non-participants were less edu-
cated, had lower income and more frequently received
social security grants [7]. There is reason to believe that
their risk profiles also differ from the respondents’ [10].
Furthermore, the results presented in Table 5 should be
interpreted with caution, due to multiple testing. The
strengths of the study were the high response rate in
HUSK, the high reliability of the measurements and
analyses carried out at the mobile screening stations, as
well as the subsequent linkage to a prescription database
comprising all prescriptions in Norway, securing a close
to complete follow-up.
The cohort of women on CVM differed from those not
on medication regarding several parameters: They had
generally lower education, their self-reported health was
poorer, and they more frequently reported muscular
pains, anxiety and depression. They also smoked more,
exercised less, and more frequently abstained from alco-
hol. Compared to men on CVM, women on treatment
reported poorer general health, more muscular pains,
anxiety, and depression. Psychosocial factors have been
extensively linked to CVD [10-12]. In a systematic review
Table 3 Cardiovascular risk scores assessed in 1997-1999 for males (n = 2 411) and females (n = 2 448) using
cardiovascular medication (CVM) in 2008 versus those not on CVM (males: n = 6 872, females: n = 8 521)1
Males Females
Risk score algorithm CVM No CVM 95% CI for difference CVM No CVM 95% CI for difference
Framingham 13.1 8.8* 3.9,4.5 5.7 3.2* 2.3,2.6
Framingham at 60 y 25.6 19.1* 6.0,6.9 12.7 8.1* 4.2,4.8
SCORE 1.8 1.2* 0.59,0.76 0.2 0.1* 0.09,0.10
SCORE at 60y 8.2 5.7* 2.3,2.7 2.1 1.4* 0.69,0.78
NORRISK 1.20 0.78* 0.36,0.47 0.32 0.20* 0.11,0.13
1Means with 95% CI for the difference.
*p < 0.001 for difference in mean risk scores for males/females on CVM, versus males/females not on CVM. Independent samples t-test.
Table 4 Proportions (numbers) of males and females
using cardiovascular medication (CVM) in 2008 by their
cardiovascular risk scores in 1997-1999
Risk score Males (n = 9 283) Females (n = 10 969)
Use of CVM (%)
Framingham 60y ≥ 20% 37.1 (n = 1 533) 56.2 (n = 356)
Framingham 60y < 20% 17.1 (n = 878) 20.2 (n = 2 092)
SCORE 60y ≥ 5% 34.6 (n = 1 712) 76.1 (n = 108)
SCORE 60y < 5% 16.1 (n = 699) 21.6 (n = 2 340)
NORRISK ≥1% 40.0 (n = 1 071) 72.6 (n = 53)
NORRISK < 1% 20.3 (n = 1 340) 21.9 (n = 2 395)
BP > 150/95 mm Hg 82.7 (n = 7 677) 87.9 (n = 9 642)
Cholesterol > 8 mmol/l 58.1 (n = 5 393) 64.4 (n = 7 064)
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of prospective cohort studies of healthy populations
Hemingway and Marmot highlighted a probable role for
among others anxiety, depression and social support in
the aetiology and prognosis of coronary heart disease
[10]. In a Dutch study, anxiety was found to predict car-
diovascular death during a 10-year follow-up among mid-
dle-aged women (hazard ratio 2.77, 95% CI 1.17,6.85)
[11], while in a study from 52 countries, the presence of
psychosocial stess was found to be associated with
increased risk of myocardial infarction [12]. In our study,
anxiety and depression correlated significantly with risk
score levels for both genders, but correlated with CVM
use only in females, while a low educational level corrre-
lated with use of CVM in both genders. In a recent
Table 5 Characteristics for females (n = 2 448) and males (n = 2 411) started on cardiovascular medication (CVM)
versus those not on treatment (females n = 8 521, males n = 6 872) in the period 1997-20081
Characteristics
1997-99
Females Males
CVM (n = 2 488) No CVM (n = 8 521) p-value* CVM (n = 2 411) No CVM (n = 6 872) p-value*
General health less than good 22.9 12.7 <0.001 16.1 10.7 <0.001
General health very good 14.1 23.5 <0.001 13.4 20.9 <0.001
Anxiety last 2 weeks1 4.2 2.5 <0.001 2.4 2.0 0.2
Depression last 2 weeks1 6.6 5.2 0.004 4.0 3.5 0.3
Muscular pain ≥ 3 months 56.0 45.9 <0.001 40.8 37.3 0.002
Use of other medication 63.7 50.4 <0.001 43.6 28.3 <0.001
Hard exercise < 1 hr/week 60.0 56.5 0.002 55.5 51.3 <0.001
Light exercise < 1 hr/week 18.3 15.0 <0.001 22.8 20.2 0.007
No use of alcohol 11.5 9.7 0.009 6.7 7.2 0.4
Daily cigarette smoking 38.0 35.8 0.04 36.5 34.5 0.07
Education < 12 years 61.8 52.8 <0.001 56.3 51.4 <0.001
Education ≥ 16 years 11.9 17.0 <0.001 15.0 18.9 <0.001
MI in relatives < 60 years 22.7 14.9 <0.001 23.0 13.7 <0.001
Stroke in relatives < 70 years 14.9 10.3 <0.001 13.0 9.2 <0.001
BMI, kg/m2, mean (SD) 26.5 (4.8) 24.3 (3.7) <0.001 27.4 (3.6) 25.7 (3.6) <0.001
SBP, mmHg, mean (SD) 132.7 (17.2) 120.8 (12.2) <0.001 138.7 (15.3) 128.7 (15.3) <0.001
DBP, mmHg, mean (SD) 76.9 (11.4) 69.3 (9.0) <0.001 82.6 (11.0) 74.7 (8.9) <0.001
Chol, mmol/l, mean (SD) 5.8 (1.1) 5.3 (0.9) <0.001 6.1 (1.3) 5.6 (1.0) <0.001
Hdl chol, mmol/l, mean (SD) 1.31 (0.38) 1.42 (0.33) <0.001 1.06 (0.26) 1.15 (0.29) <0.001
TG, mmol/l, mean (SD) 1.72 (1.16) 1.29 (0.73) <0.001 2.62 (2.17) 1.99 (1.20) <0.001
Glucosis, mmol/l, mean (SD) 5.3 (1.4) 5.0 (0.9) <0.001 5.5 (1.3) 5.2 (1.0) <0.001
1Figures are proportions unless otherwise stated.
Myocardial infarction (MI), Body mass Index (BMI) Standard deviation (SD).
Systolic Blood Pressure (SBT); Diastolic Blood Pressure (DBT); High Density Lipid (HDL); TriGlycerides (TG).
1Substantially or very much bothered.
*p-value for difference in propotions or in mean levels of each characteristic for females/males using CVM versus females/males not using CVM (chi square test/
independentsamples t-test).
Table 6 Mean CVD risk scores (SD) related to mental distress
Risk score Males Females)
Anxiety Depression Anxiety Depression
Yes
n = 186
No
n = 8618
Yes
n = 317
No
n = 8492
Yes
n = 293
No
n = 9908
Yes
n = 561
No
n = 9966
Framingham 12.1 (6.9) 9.9* (6.1) 11.1 (6.5) 9.9* (6.2) 5.1 (4.0) 3.7* (3.5) 4.5 (3.8) 3.7* (3.5)
SCORE 1.67 (1.16) 1.33* (1.87) 1.54 (1.12) 1.33* (1.88) 0.20 (0.16) 0.16* (0.15) 0.18 (0.17) 0.16* (0.15)
NORRISK 1.08 (0.69) 0.87* (0.61) 1.00 (0.65) 0.88* (0.61) 0.27 (0.20) 0.23* (0.18) 0.25 (0.19) 0.23* (0.18)
*p < 0.01 (independent samples t-test) for difference in risk score by categories of self reported mental distress.
Yes = substantially or very much bothered.
No = not or a little bothered.
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Finnish study an association was found between psycho-
logical distress and cardiovascular risk scores (Framing-
ham and SCORE) for men, but not for women [13]. Our
results may reflect that clinicians, in particular for female
patients, tend to include features like mental distress and
social situation when deciding if and when a patient
needs CVM [14].
In our study population covering a possible age span
from 40 to 58 years, more than one in four males and
one in five females had started on CVM during a dec-
ade. Recommended risk algorithms for CVD at baseline
only to a limited degree correlated with later medication
use, especially in females, while psychosocial factors cor-
related stronger with use of CVM in females compared
to males. Possible reasons for underusing total risk
assessment tools in clinical practice may be that the
tools are considered inaccurate or poorly validated.
Whether their use improves patient outcomes has in
fact rarely been evaluated [15-17]. Furthermore, critics
have emerged that guidelines for preventive cardiology
(which form the basis for the application of the risk
assessment tools) tend to overestimate CVD risk and
hence target a too large share of the population for risk
interventions [18,19]. The Framingham equations have
been found to over-predict coronary events by 57%
compared with observed events in a representative sam-
ple of British men [20]. NORRISK is more adapted to
the current Norwegian risk situation compared to the
SCORE and Framingham algorithms, both of which
have been found to overestimate the risk of fatal CVD
in Norway [21]. However, our study reveals that none of
the three risk algoritms proved to be superior to the
others in order to predict subsequent use of CVM in a
middle aged cohort. Most females on medication had
risk score values well below risk-thresholds, while less
than half of men with values above the threshold limits
used CVM.
The newly developed CVD risk score QRISK2 includes
the traditional Framingham risk factors, but also
includes BMI, a family history of CVD, social class mea-
sured by Townsend score, self-assigned ethnicity, and
presence of several listed diseases known to be asso-
ciated with CVD, among others diabetes mellitus and
rheumatoid arthritis [4]. This score has been externally
validated, and is found to predict cardiovascular risk
more accurately than the Framingham score [22].
Official guidelines on calculating global risk were
implemented in Norway in 2009, that is after our data
collection took place, but GPs had already been edu-
cated in global risk assessment during the previous 20
years, through guidelines provided by the National Col-
lege of GPs. We would therefore expect the average
physician to be informed about the recommendations
regarding total risk assessment in 2008. But even if
clinicians do calculate patients’ total risk score, little is
known about how this knowledge affects the physicians’
decision making in terms of prescribing CVM [17]. We
have not found any earlier study linking use of CVM
directly to CVD-risk in a selected population cohort.
The results of our study indicate that clinicians still
probably tend to base their prescription decisions on
other features than a total CVD risk assessment: a
family history of CVD, single risk-factor assessment (ele-
vated BP- or lipid values), or psychosocial factors. In our
study, the strongest correlation between one single mea-
sure and CVM was found for BP. With a BP > 150/95,
as many as 83% of men and 88% of women received
drug treatment. However, we still have limited knowl-
edge on how clinicians decide which patient to put on
treatment, and when. Such knowledge is important to
ensure that the relatively large population share on
CVM includes those individuals who will benefit most
from using them, probably for the rest of their lives.
Conclusion
Prescription of cardiovascular medication to middle-
aged persons to a large degree was found to occur inde-
pendently of the indviduals’ total cardiovascular risk,
especially in women. Despite their substantially lower
total cardiovascular risk, middle aged women by large
recieved as much cardiovascular medications as men. At
least eight out of ten middle aged women using cardio-
vascular medication in 2008 had cardiovascular risk
scores (Framingham, SCORE, NORRISK) below defined
“high-risk” thresholds ten years before.
Cardiovascular drug prescription practice still seems
to be based on single factor assessments (blood pres-
sure, lipid level, family history of CVD), but psychosocial
factors seem to influence which patients will be put on
treatment, especially in women.
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